Predictors of tuberculosis treatment success under the DOTS program in Namibia

References

• Republic of Namibia Ministry of Health and Social Services. National guidelines for the management of tuberculosis. 2011. 3rd ed. Available from: http://www.who.int/hiv/pub/guidelines/namibia_tb.pdf
   Google Scholar
• Corbett EL, Marston B, Churchyard GJ, et al. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 2006;367(9514):926–937.
   PubMed Web of Science ®Google Scholar
• Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57–72.
   PubMed Web of Science ®Google Scholar
• WHO. Use of high burden country lists for TB by WHO in the post-2015 era. 2015. [cited 2018 May 25]. Available from: http://www.who.int/tb/publications/global_report/high_tb_burdencountrylists2016-2020summary.pdf
   Google Scholar
• WHO. The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millennium Development Goals. 2006. [cited 2018 May 24]. Available from: http://apps.who.int/iris/bitstream/handle/10665/69241/WHO_HTM_STB_2006.368_eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• Thiam S, LeFevre AM, Hane F, et al. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. Jama. 2007;297(4):380–386.
   PubMed Web of Science ®Google Scholar
• World Health Organization. What Is DOTS? A Guide to Understanding the WHO-Recommended TB Control Strategy Known as DOTS. 1999. [cited 2018 May 25]. Available from: http://apps.who.int/iris/bitstream/handle/10665/65979/WHO_CDS_CPC_TB_99.270.pdf?sequence=1&isAllowed=y
   Google Scholar
• Borgdorff MW, Floyd K, Broekmans JF. Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull World Health Organ. 2002;80(3):217–227.
   PubMed Web of Science ®Google Scholar
• WHO. GLOBAL TUBERCULOSIS REPORT. 2016. [cited 2018 May 25]. Available from: http://apps.who.int/medicinedocs/documents/s23098en/s23098en.pdf
   Google Scholar
• Tanday S. Will we ever eliminate tuberculosis, the voiceless disease?. Lancet Respir Med. 2017 Mar 15;5(4):256-257.
   PubMed Web of Science ®Google Scholar
• van Gorkom J, Mavhunga F, Omer OA, et al. TB control in Namibia 2002–2011: progress and technical assistance. Open Infect Dis J. 2013;7(SPECISS1):23–29.
   Google Scholar
• Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ. 2005;331(7529):1364.
   PubMedGoogle Scholar
• Republic of Namibia Ministry of Health and Social Services. Republic of Namibia ministry of health and social services national tuberculosis and leprosy programme annual report: 2014–2015. Namibia: Windhoek; 2015.
   Google Scholar
• Laxminarayan R, Klein EY, Darley S, et al. Global investments in TB control: economic benefits. Health Aff. 2009;28(4):w730–w742.
   Web of Science ®Google Scholar
• Ministry of Health and Social Services. National Tuberculosis and Leprosy Programme Summary Report 2014–15. 2015.
   Google Scholar
• WHO. WHO | tuberculosis. WHO. 2016. [cited 2018 May 25]. Available from: http://www.who.int/mediacentre/factsheets/fs104/en/.
   Google Scholar
• World Health Organization. Global Tuberculosis Report; Switzerland: WHO Press. 2016.
   Google Scholar
• Studies H, Ehlers U, Unisa HS. Factors associated with community-based TB care in the omaheke region, Namibia. Africa Journal of Nursing and Midwifery. 2007;9(1):59–72.
   Google Scholar
• WHO. MDR-TB. [cited 2018 May 24]. Available from: http://www.who.int/tb/challenges/mdr/MDR-RR_TB_factsheet_2017.pdf
   Google Scholar
• Zvavamwe Z, Ehlers VJ. Experiences of a community-based tuberculosis treatment programme in Namibia: a comparative cohort study. Int J Nurs Stud. 2009;46(3):302–309.
   PubMed Web of Science ®Google Scholar
• Seeling S, Mavhunga F, Thomas A, et al. Barriers to access to antiretroviral treatment for HIV-positive tuberculosis patients in Windhoek, Namibia. Int J Mycobacteriology. 2014;3(4):268–275.
   PubMedGoogle Scholar
• DeRiemer K, García-García L, Bobadilla-del-Valle M, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet. 2005;365(9466):1239–1245.
   PubMed Web of Science ®Google Scholar
• Huynh GH, Klein DJ, Chin DP, et al. Tuberculosis control strategies to reach the 2035 global targets in China: the role of changing demographics and reactivation disease. BMC Med. 2015;13(1):88.
   PubMedGoogle Scholar
• Acosta CD, Rusovich V, Harries AD, et al. A new roadmap for childhood tuberculosis. Lancet Glob Heal. 2014;2(1):e15–e17.
   PubMed Web of Science ®Google Scholar
• Nakiyingi L, Bwanika JM, Kirenga B, et al. Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS One. 2013;8:9.
   Web of Science ®Google Scholar
• Namukwaya E, Nakwagala FN, Mulekya F, et al. Predictors of treatment failure among pulmonary tuberculosis patients in mulago hospital, Uganda. Afr Health Sci. 2011;11(Suppl 1):S105–s11.
   PubMedGoogle Scholar
• Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis. 2011;15(7):871–885.
   PubMed Web of Science ®Google Scholar
• WHO. Best Practices in Prevention, Control and Care for Drug Resistant Tuberculosis. 2017. [cited 2018 May 22]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0020/216650/Best-practices-in-prevention,control-and-care-for-drugresistant-tuberculosis-Eng.pdf
   Google Scholar
• MoHSS. Republic of Namibia Ministry of Health and Social Services National Tuberculosis and Leprosy Programme Annual Report : 2014–2015; 2015.
   Google Scholar
• Kapoor SK, Raman AV, Sachdeva KS, et al. How did the TB patients reach DOTS services in Delhi? A study of patient treatment seeking behavior. PLoS One. 2012;7:8.
   Google Scholar
• Uplekar M, Weil D, Lonnroth K, et al. WHO’s new end TB strategy. Lancet. 2015;385(9979):1799–1801.
   PubMed Web of Science ®Google Scholar
• Pn MUJASI. Matlakala MC factors associated with health seeking behaviour of pulmonary tuberculosis patients in Butaleja District in Uganda. Afr J Phys Health Educ Recreat Dance. 2014;20(3):841–857.
   Google Scholar
• Oxlade O, Piatek A, Vincent C, et al. Modeling the impact of tuberculosis interventions on epidemiologic outcomes and health system costs. BMC Public Health. 2015;15(1):141.
   PubMedGoogle Scholar
• Sesay ML Patient Characteristics and Treatment Outcomes Among Tuberculosis Patients in Sierra Leone. 2017. [cited 2018 May 23]. Available from: https://scholarworks.waldenu.edu/cgi/viewcontent.cgi?article=4680&context=dissertations
   Google Scholar
• Chida N, Ansari Z, Hussain H, et al. Determinants of default from tuberculosis treatment among patients with drug-susceptible tuberculosis in Karachi, Pakistan: a mixed methods: study. PLoS One. 2015;10(11):1–14.
   Web of Science ®Google Scholar
• Verbeeck RK, Günther G, Kibuule D, et al. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Eur J Clin Pharmacol. 2016;72(8):905–916.
   PubMed Web of Science ®Google Scholar
• Marx FM, Dunbar R, Enarson DA, et al. The rate of sputum smear-positive tuberculosis after treatment default in a high-burden setting: a retrospective cohort study. PLoS One. 2012;7(9):1–9.
   Web of Science ®Google Scholar
• Lienhardt C, Manneh K, Bouchier V, et al. Factors determining the outcome of treatment of adult smear-positive tuberculosis cases in The Gambia. Int J Tuberc Lung Dis. 1998;2(9):712–718.
   PubMed Web of Science ®Google Scholar
• Sinshaw Y, Alemu S, Fekadu A, et al. TB treatment outcome and its associated factors among TB/HIV co-infected patients attending Gondar University Referral Hospital, Northwest Ethiopia: an institution based cross-sectional study. BMC Infect Dis. 2017;17(1):132.
   PubMedGoogle Scholar
• van Hest R, Ködmön C, Verver S, et al. Tuberculosis treatment outcome monitoring in European Union countries: systematic review. Eur Respir J. 2013;41(3):635–643.
   PubMed Web of Science ®Google Scholar
• Choi R, Jeong B-H, Koh W-J, et al. Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations. Ann Lab Med. 2017;37(2):97.d.
   Web of Science ®Google Scholar
• Baboli MT, Abdolmaleki EY, Shirzad M, et al. Prevalence of drug-induced hepatitis and its risk factors in the treatment of tuberculosis in TB infected patients attending Razi hospital, 2006–2011. [Persian]. J Maz Univ Med Sci. 2014;24(109):235–240.
   Google Scholar
• Sagwa E, Mantel-Teeuwisse AK, Ruswa N, et al. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. South Med Rev. 2012;5(1):6–13.
   PubMedGoogle Scholar
• Garfein RS, Collins K, Muñoz F, et al. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. Int J Tuberc Lung Dis. 2015;19(9):1057-1064.
   Web of Science ®Google Scholar
• Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. Jama. 2000;283(19):2537–2545.
   PubMed Web of Science ®Google Scholar
• Vasankari T, Holmstrom P, Ollgren J, et al. Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study. BMC Public Health. 2007 Oct;14(7):291.
   Google Scholar
• Hung CL, Chien JY, Ou CY. Associated factors for tuberculosis recurrence in Taiwan: a nationwide nested case-control study from 1998 to 2010. PLoS One. 2015;10(5):1–11.
   Web of Science ®Google Scholar
• NM de F G, Bastos MCDM, Rm M, et al. Differences between risk factors associated with tuberculosis treatment abandonment and mortality. Pulm Med. 2015;2015:1–8.
   Google Scholar
• Oshi DC, Oshi SN, Alobu I, et al. Profile, outcomes, and determinants of unsuccessful tuberculosis treatment outcomes among HIV-infected tuberculosis patients in a Nigerian State. Tuberc Res Treat. 2014;2014:202983.
   PubMedGoogle Scholar
• Sotgiu G, Alffenaar J-WC, Centis R, et al. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. Int J Infect Dis. 2015;32:101–104.
   PubMed Web of Science ®Google Scholar